ArticleCell reports. Medicine2022

Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts.

Benjamin P Sharpe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.